Organon and Radboud University Nijmegen Medical Centre announce new research collaboration
The collaboration will leverage Organon's proprietary monoclonal antibody technology and the Medical Centre's expertise in oncology to investigate whether the target - that is indicated to be involved in tumor growth - may form the basis of a novel cancer treatment.
"This exciting research collaboration reflects Organon's determination to strengthen its existing biotechnology expertise and expand our activities into the oncology field," said David Nicholson, Executive Vice President Research and Development, Organon International, "The early work will be undertaken by scientists at our Organon Research Center USA in Cambridge, Massachusetts recently established to expand the breadth and depth of our biotechnology research program."
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.